Literature DB >> 25800142

Within-class differences of the sulfonylureas should be accounted for.

Dennis Schrijnders1, Nanne Kleefstra, Gijs W D Landman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25800142     DOI： 10.1007/s00125-015-3556-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Authors:  C Filozof; J-F Gautier
Journal:  Diabet Med       Date:  2010-03       Impact factor: 4.359

2.  A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Authors:  Azim S Gangji; Tali Cukierman; Hertzel C Gerstein; Charles H Goldsmith; Catherine M Clase
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

3.  Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.

Authors:  J E Foley; S Sreenan
Journal:  Horm Metab Res       Date:  2009-08-24       Impact factor: 2.936

4.  The effect of glibenclamide on insulin secretion at normal glucose concentrations.

Authors:  Axel Riefflin; Usha Ayyagari; Susan E Manley; Rury R Holman; Jonathan C Levy
Journal:  Diabetologia       Date:  2014-10-09       Impact factor: 10.122

5.  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

Authors:  Tina Ken Schramm; Gunnar Hilmar Gislason; Allan Vaag; Jeppe Nørgaard Rasmussen; Fredrik Folke; Morten Lock Hansen; Emil Loldrup Fosbøl; Lars Køber; Mette Lykke Norgaard; Mette Madsen; Peter Riis Hansen; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2011-04-06       Impact factor: 29.983

6.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

Authors: 
Journal:  Am J Kidney Dis       Date:  2012-11       Impact factor: 8.860

7.  GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.

Authors:  G Schernthaner; A Grimaldi; U Di Mario; J Drzewoski; P Kempler; M Kvapil; A Novials; R Rottiers; G E H M Rutten; K M Shaw
Journal:  Eur J Clin Invest       Date:  2004-08       Impact factor: 4.686

Review 8.  Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.

Authors:  Gijs W D Landman; Geertruide H de Bock; Kornelis J J van Hateren; Peter R van Dijk; Klaas H Groenier; Rijk O B Gans; Sebastiaan T Houweling; Henk J G Bilo; Nanne Kleefstra
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240
  8 in total
  2 in total

Review 1.  Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment.

Authors:  Viswanathan Mohan; Kamlesh Khunti; Siew P Chan; Fadlo F Filho; Nam Q Tran; Kaushik Ramaiya; Shashank Joshi; Ambrish Mithal; Maïmouna N Mbaye; Nemencio A Nicodemus; Tint S Latt; Linong Ji; Ibrahim N Elebrashy; Jean C Mbanya
Journal:  Diabetes Ther       Date:  2019-11-26       Impact factor: 2.945

2.  Modern Sulfonylureas Strike Back - Exploring the Freedom of Flexibility.

Authors:  Sanjay Kalra; Deepak Khandelwal
Journal:  Eur Endocrinol       Date:  2018-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.